Novo Nordisk A/S (NVO) Stock: Surge as Sogroya Wins Key EU Recommendation for Children

TLDR

• Sogroya earns EU panel backing for children with idiopathic short stature treatment.
• Novo Nordisk stock rises as Sogroya clears an important European regulatory hurdle.
• REAL8 data showed weekly Sogroya matched daily growth hormone therapy at 52 weeks.
• EU regulators will now review broader approval across three child indications.
• Sogroya could become the EU’s first approved therapy for idiopathic short stature.

Novo Nordisk (NVO) shares gained regulatory momentum after a European medicines panel backed Sogroya for children with idiopathic short stature. NVO stock traded at $43.24, gaining 0.12% after recovering from a sharp mid-morning decline. The recommendation could expand Sogroya’s reach across Europe if regulators grant final marketing approval.

Novo Nordisk A/S, NVO

Sogroya Secures Key CHMP Recommendation

The European Medicines Agency’s CHMP recommended once-weekly Sogroya for children with idiopathic short stature and persistent growth problems. The decision moves Novo Nordisk closer to securing another European indication for its long-acting growth hormone treatment. Idiopathic short stature affects children who remain significantly shorter than peers without an identifiable underlying medical cause.

The condition affects up to 3% of children worldwide, but diagnosis and treatment options remain limited in several regions. Many children receive referrals late, which can shorten the available treatment window before growth slows during adolescence. Therefore, broader recognition could support earlier diagnosis and provide families with clearer treatment pathways.

Novo Nordisk developed Sogroya as a once-weekly injection that uses albumin-binding technology to extend its activity inside the body. This design reduces injection frequency compared with traditional growth hormone treatments that patients may receive every day. The treatment could offer a simpler dosing schedule for eligible children and their families.

REAL8 Trial Supports Weekly Growth Hormone Treatment

Novo Nordisk supported the latest regulatory submission with findings from its REAL8 clinical trial. The study assessed Sogroya in children with idiopathic short stature and other conditions linked to impaired growth. Researchers compared the once-weekly treatment with standard daily growth hormone therapy during the 52-week trial period.

Trial results showed that Sogroya achieved comparable annualized height growth against daily growth hormone treatment after 52 weeks. The findings covered children with idiopathic short stature, Noonan syndrome, and those born small for gestational age. These results provided the clinical basis behind the CHMP’s positive recommendation for the additional pediatric indications.

Sogroya already holds European authorization for treating growth hormone deficiency in both adults and children. European regulators approved the treatment for adults in March 2021 and expanded approval to children in July 2023. The latest recommendation could broaden its role beyond growth hormone deficiency into additional causes of short stature.

European Commission Decision Remains Next Step

The CHMP previously recommended Sogroya for Noonan syndrome and children born small for gestational age during May 2026. The new recommendation now adds idiopathic short stature to the proposed expansion of the treatment’s European authorization. Novo Nordisk expects the European Commission to decide on all three proposed indications later in 2026.

Children born small for gestational age may have reduced weight, length, or head circumference compared with expected birth measurements. Most children later reach normal growth levels, although some fail to achieve adequate catch-up growth during early childhood. Doctors may refer these children to pediatric endocrinologists when growth remains limited after two or three years.

Idiopathic short stature can also create social and emotional challenges when children remain significantly shorter than their peers. However, medical diagnosis requires doctors to exclude other possible causes before confirming the condition. Final European approval would make Sogroya the first growth hormone specifically approved for idiopathic short stature across the European Union.

The post Novo Nordisk A/S (NVO) Stock: Surge as Sogroya Wins Key EU Recommendation for Children appeared first on Blockonomi.